{"groups":[{"description":"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin (PLD)+ Lenalidomide (DVD-R) Therapy:\n\nPer 28 Day Cycle, patients will received drug in the following order, dosing and schedule:\n\n1\\) Dexamethasone- 40 mg intravenous infusion (IV) on Days 1, 4, 8 and 11; 2) Bortezomib- 1.0 mg/m2 infused over 3 to 5 seconds followed by a standard saline flush on Days 1, 4, 8 and 11; 3) Pegylated Liposomal Doxorubicin- 4.0 mg/m2 IV as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle; and 4) Lenalidomide- 10 mg PO on days 1-14","id":"FG000","title":"DVD-R Single Arm"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"inclusion/exclusion criteria failure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"22"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study enrolled patients from eight different clinical sites sites in the United States. Data was collected from September 2009 until July 25, 2011"}